Inflammatory marker may highlight aggressive RCC treatment need News-Medical.net “The introduction of molecular-targeted agents following cytoreductive nephrectomy may result in the improved survival of patients with mRCC compared with cytokine therapy alone,” the researchers conclude. But they stress that it may be “necessary to ... |
